The recent cloning of a second estrogen receptor (ER), designated ERb, has prompted a reevaluation of the role of ERs in breast cancer. We have developed and validated a real-time RT ± PCR assay to quantify ERa and ERb gene expression at the mRNA level in a series of 131 patients with unilateral invasive primary breast cancer. Although ERb expression showed wide variations in tumor tissues, its range (nearly three orders of magnitude) was smaller than that of ERa (nearly four orders of magnitude), suggesting that ERb is more tightly controlled than ERa. We observed a negative correlation between ERa and ERb expression.`ERa-negative' tumors (containing very low ERa mRNA levels) were associated with SBR histopathological grade III, RB1 underexpression and ERBB2 overexpression, con®rming that ERa negativity delineates poorly dierentiated tumors. The amount of ERa mRNA (but not that of ERb mRNA) increased with age and was consequently higher in postmenopausal patients' tumors. Expression of ERa (but not that of ERb) also correlated strongly with progesterone receptor (PR) and PS2 expression, suggesting that ERa has stronger transcriptional activity than ERb towards genes containing an ERE (estrogen response element) in their promoters. Interestingly, we found a negative correlation between the expression of ERb (but not ERa) and CCND1, which contains an AP1 element but not an ERE in its promoter. Taken together, these data con®rm that ERa and ERb play dierent roles in breast cancer, partly by mediating the transcription of various genes via dierent types of DNA enhancer. PR and PS2 seem to be mainly ERaresponsive genes, whereas CCND1 may be mainly ERbresponsive. Our ®ndings also underline the need for a reliable method, providing full range of quantitative values, to determine ERa and ERb status in the clinical setting. Oncogene (2001) 20, 8109 ± 8115.
Introduction
Estrogens not only regulate the growth and development of normal human mammary tissue but are also involved in breast cancer progression. The action of estrogen is mediated by ER (estrogen receptor). ER measurement is widely used in the clinical management of breast cancer, particularly to identify tumors resistant to tamoxifen. ER is mainly measured by means of ligand binding assays, and more recently by immunohistochemical approaches.
A new estrogen receptor subtype, designated ERb, was recently isolated (Kuiper et al., 1996; Mosselman et al., 1996) , indicating that the mechanism of estrogen action is far more complex than previously thought. ERb expression in breast cancer has mainly been studied at the mRNA level (Dotzlaw et al., 1999; Speirs et al., 1999; Knowlden et al., 2000; Kurebayashi et al., 2000) . Pilot studies of small series of breast tumors point to a dierent tissue distribution of ERb and ERa (the previously known ER), as well as far weaker ERb than ERa expression (Knowlden et al., 2000; . These ®ndings may explain diculties in raising speci®c antibodies against human ERb protein.
As ERb and ERa seem to have dierent ligand binding speci®city (Kuiper et al., 1996; Paech et al., 1997) , ERb determination may provide additional information on the responsiveness of breast cancers to dierent endocrine treatments.
To further explore the respective roles of ERa and ERb in breast carcinogenesis, we quanti®ed the expression of the two genes in a series of 131 unilateral invasive primary breast tumor RNAs by means of realtime quantitative RT ± PCR, in the same homogeneous total RNA solutions. This recent method of nucleic acid quanti®cation in homogeneous solutions has the potential to become a standard in terms of its performance, accuracy, sensitivity, broad dynamic range, high throughput capacity, good inter-laboratory agreement, and the fact that it yields statistical con®dence values (Gibson et al., 1996) .
We also examined the relationship between ERa and ERb expression status and classical clinical and pathological parameters, and patient outcome. ERa and ERb mRNA levels were also compared with those of two well-known ER-responsive genes (PR and PS2), and four genes among the most frequently altered genes in breast cancer to date, i.e. RB1, CCND1, MYC and ERBB2.
Results

ERa mRNA expression in breast tumor tissues
NERa values (calculated as described in Materials and methods) ranged from 1 to 5890 (mean 1060+standard deviation 1243) for the 131 breast tumor RNA samples tested, i.e. a spread of nearly four orders of magnitude.
Thirty tumors had very low levels of ERa mRNA (mean 8.5+standard deviation 4.3) compared to the other tumors (mean 1390+standard deviation 1314), showing a clear bimodal ERa distribution. A natural cuto point of NERa=20 was subsequently used to distinguish these two populations. Interestingly, nearly all these 30 tumors lacked transcriptional transactivation of the two well-known ER-responsive genes PR and PS2, con®rming that there is a biological rationale for this speci®c cuto point. These 30 tumors were thus categorized as`ERa negative'.
To better analyse the correlations between ERa mRNA levels and clinical and biological parameters, we then subdivided the 101`ERa-positive' tumors into tertiles (three equal groups: n=34, 34 and 33), with low (27 ± 320), intermediate (321 ± 1040) and high (1041 ± 5890) NERa values.
ERb mRNA expression in breast tumor tissues
NERb values for the 131 breast tumor RNA samples ranged from 1 to 549 (mean 66+standard deviation 92), i.e. nearly three orders of magnitude. ERb transcript levels were between 10 2 and 10 3 -fold lower than ERa transcript levels (data not shown).
Contrary to ERa, NERb values were not bimodally distributed and there is no biological rationale for speci®c cuto points; we therefore divided the 131 tumors into tertiles (three equal groups: n=44, 44, and 43), with low (1 ± 17), intermediate (18 ± 55) and high (56 ± 549) NERb values.
Correlation between ERa and ERb mRNA levels
As shown in Table 1 ERa and ERb status were not signi®cantly linked to lymph-node status, macroscopic tumor size, or relapse (Table 2 ). Disease-free survival after surgery was not found to be dierent between patients with high and low ERa or ERb mRNA levels (log-rank test; data not shown).
Relationship of ERa and ERb mRNA levels with PR and PS2 expression status (Table 3) Tumors were divided into three equal groups with low (n=43), intermediate (n=44) and high (n=44) PR or PS2 mRNA levels.
ERa mRNA levels (but not ERb mRNA levels) were strongly correlated with both PR mRNA levels (P510 77 ) and PS2 mRNA levels (P510 77 ). It is noteworthy that we observed three ERanegative tumors (10%) having intermediate PR mRNA levels, and two ERa-negative tumors (6.6%) having intermediate or high PS2 mRNA levels ( Table 3 ). The three ERa-negative tumors expressed PR mRNA levels did not correspond to the two ERa-negative tumors expressing PS2 mRNA levels. The ERa, PR and PS2 mRNA status of these ®ve tumors was con®rmed in repeat real-time quantitative RT ± PCR analyses.
Conversely, some tumors with high ERa mRNA levels had low PR and/or PS2 mRNA levels.
Relationship of ERa and ERb mRNA expression status with RB1, CCND1, MYC and ERBB2 expression status
The 131 tumors studied for ERa and ERb mRNA expression had previously been tested for RB1, CCND1, MYC and ERBB2 mRNA expression (BieÁ che et al., 1999a,b; BieÁ che and Lidereau, 2000; and manuscript submitted) . The results (summarized in Table 3 ) showed a statistically signi®cant association between ERa negativity and both RB1 underexpression and ERBB2 overexpression (P=0.0087 and P=0.033, respectively). No such associations were observed with ERb mRNA status. We also found a signi®cant association of CCND1 overexpression with low ERb mRNA levels (P=0.027) but not with ERa mRNA levels. This negative correlation between ERb and CCND1 mRNA levels was con®rmed by the Spearman rank correlation test (r=70.288, P=0.0010). Finally, no link was found between MYC overexpression and ERa or ERb mRNA levels.
Discussion
We used real-time quantitative RT ± PCR to assess ERa and ERb expression in human breast tumors. This recent approach to nucleic acid quanti®cation is suited to the development of target gene assays, having a high degree of inter-laboratory standardization and also -fold lower), in good agreement with previous data (Knowlden et al., 2000) . These two ®ndings suggest that the development of ERb-speci®c antibodies and the standardization of immunohistochemical methods for determining ERb status may be problematic.
Thirty of the 131 breast tumors tested had very low levels of ERa mRNA, yielding a bimodal distribution around a natural cuto of NERa=20. The two tumor subpopulations are hereafter referred to as ERanegative and ERa-positive, respectively. No such distinction was observed in terms of ERb expression.
All but one of these 30 ERa-negative tumors had already been designated ERa-negative in biochemical assay (data not shown). The single biochemical assaypositive, RT ± PCR-negative tumor probably re¯ect tumor heterogeneity. In addition, we observed 12 biochemical assay-negative tumors with low ERa mRNA levels (NERa from 21 to 320) in real-time quantitative RT ± PCR, and with clear emergence of transcriptional transactivation of the two ER-responsive genes: PR and PS2. These data re¯ect the higher sensitivity of this RT ± PCR-based assay relative to cytosol steroid-binding and immunohistochemical methods. We also observed a high correlation between ERa mRNA level and ER protein content, analysed as quantitative variables (Spearman rank correlation test; r=+0.707, P510
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; data not shown). The 30 ERa-negative tumors were associated with SBR histopathological grade III, RB1 underexpression and ERBB2 overexpression, con®rming that ERanegativity is a marker of tumor aggressiveness (poorly dierentiated tumors) in human breast cancer. The ERb expression level was not signi®cantly related to these parameters.
RT ± PCR assay results were also used to subdivide the 101 ERa-positive tumors and the 131 ERb-positive tumors into three equal groups with low, intermediate and high mRNA levels. This yielded several interesting ®ndings: (a) a negative correlation between ERa and ERb mRNA levels (Table 1) , in agreement with previous data (Knowlden et al., 2000; Leygue et al., 1998) . This negative correlation was also observed between ER protein content and ERb mRNA level, analysed as quantitative variables (Spearman rank correlation test; r=70.416, P=0.0000028; data not shown). It is noteworthy that a correlation has previously been suggested between the ERb mRNA copy number and ERb protein abundance (Fuqua et al., 1999; JaÈ rvinen et al., 2000) . However, further studies are necessary to con®rm that alteration of ERb gene expression is exclusivement regulated at the transcriptional level. (b) Among the 101 ERa-positive tumors, the amount of ERa mRNA was higher in those from both elderly and postmenopausal women (Table 2 ). This association with age and postmenopausal status was not observed for ERb mRNA. It may possibly be explained by upregulation of ERa expression to compensate for the declining supply of circulating sex steroids. Diab et al. (2000) showed an association between increasing age at breast cancer diagnosis and favorable biological characteristics, including ERa-positivity. This high frequency of ERa-positivity and the stronger ERa expression in older patients should be considered when making clinical decisions. These ®ndings also point to the need for a technique providing the full range of quantitative values for ERa status, which is not the case of immunohistochemical methods. (c) ERa expression (but not ERb expression) correlated strongly with PR and PS2 expression, suggesting that these two latter genes are mainly ERa-responsive, and that ERa mainly mediates gene transcription via the classical ERE (estrogen response element). We observed rare cases of ERa-negative tumors expressing intermediate or high PR or PS2 mRNA levels, and several tumors with high ERa mRNA levels expressing very low levels of PR and/or PS2 mRNA (Table 3) , in keeping with previous reports (Soubeyran et al., 1996) . It is noteworthy that, using the same methodology and the same homogeneous total RNA solutions to quantify the expression of dierent genes, we observed a lower frequency of ERa+/PS27 (1.5%) and ERa+/ PR7 (2.3%) tumors than previously reported (5 ± 15% each) (Soubeyran et al., 1996; Group EBCTC, 1998) . (d) Most interestingly, ERb expression (but not ERa expression) showed a negative link with the expression of CCND1, an estrogen-responsive gene containing an AP1 element but not an ERE in its promoter. This negative correlation between ERb and CCND1 mRNA levels was con®rmed on an additional series of 132 breast tumor RNAs from postmenopausal women (Spearman test, r=70.171, P=0.048; data not shown). These results are in agreement with data obtained in vitro by Paech et al. (1997) showing that ERb inhibits gene transcription via the AP1 element. Moreover, Planas-Silva et al. (1999) showed that the regulation of CCND1 expression by estrogen is mediated by the actions of AP1. In consequence, CCND1 may be a speci®c ERb-responsive gene. As CCND1 participates in controlling the G1-S transition of the cell cycle, and as CCND1 overexpression accelerates proliferation, our data suggest that ERb activation may suppress proliferation (via downregulation of CCND1) and that antiestrogen binding to ERb may favor cell proliferation and malignant transformation (via upregulation of CCND1). This may be important in terms of antiestrogen resistance.
However, further studies are necessary to con®rm that CCND1 is a speci®c ERb-responsive gene, with evidence of direct (or indirect) transcriptional regulation of CCND1 gene throughout ERb.
In conclusion, these data suggest that ERa and ERb play dierent roles in gene regulation, and thus in breast cancer, and that the relative expression level of the two genes should be a key determinant of cellular responses to estrogen agonists and antagonists. In consequence, it may be interesting to determine the expression level of the two ER subtypes when attempting to predict the response to endocrine therapy in breast cancer.
Finally, the cost-eective, rapid, highly sensitive, high-throughput RT ± PCR assay used here to determine the full range of ERa and ERb mRNA values could be a valuable alternative to immunochemistry as a routine tool in the clinical setting.
Materials and methods
Patients and samples
We analysed tissue from primary breast tumors excised from 131 women at the Centre ReneÂ Huguenin from 1977 to 1989. The samples were examined histologically for the presence of tumor cells. A tumor sample was considered suitable for this study if the proportion of tumor cells exceeded 60%. Immediately following surgery the tumor samples were stored in liquid nitrogen until RNA extraction.
The patients (mean age 58.2 years, range 34 ± 91 years) met the following criteria: primary unilateral non metastatic breast carcinoma for which complete clinical, histological and biological data were available; and no radiotherapy or chemotherapy before surgery. The main prognostic factors are shown in Table 4 . The median follow-up was 8.1 years (range 1.0 ± 15.9 years). Forty-seven patients relapsed; the ®rst relapse events were as follows: 13 local and/or regional recurrences, 30 metastases, and both in four cases.
Evaluation of`classical' prognostic factors
The histological type and steroid-hormone receptor status of each tumor were established at the time of surgery, together with the number of invaded axillary nodes. The malignancy of in®ltrating carcinomas was scored according to ScarBloom-Richardson classi®cation (Bloom and Richardson, 1957) . Estrogen receptor status was assayed on cytosol, either by a ligand-binding assay (Dextran-Coated Charcoal method) as described by the European Organisation for Research and Treatment of Cancer (EORTC, 1980) , or by a enzyme immunoassay (Abbott laboratories, Abbott Park, IL, USA) using monoclonal antibodies D547 and H222 (Jensen et al., 1987) . The cut-o used to classify tumors as ER positive or negative was 10 fmol/mg cytosolic protein for the ligand-binding assay, and 15 fmol/mg cytosolic protein for the enzyme immunoassay.
Real-time RT ± PCR
Theoretical basis Quantitative values are obtained from the threshold cycle number at which the increase in the signal associated with exponential growth of PCR products begins to be detected using PE Biosystems analysis software according to the manufacturer's manuals.
The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both dicult to assess. We therefore also quanti®ed transcripts of the RPLP0 gene (also known as 36B4) encoding human acidic ribosomal phosphoprotein P0 as the endogenous RNA control, and each sample was normalized on the basis of its RPLP0 content.
The target (ERa, ERb, PR or PS2) relative gene expression level was also normalized to a calibrator, or 1X sample, consisting of the breast tumor sample in the test series which contained the smallest amount of target gene mRNA.
Final results, expressed as N-fold dierences in target gene expression relative to the RPLP0 gene and the calibrator, and designated`NTARGET', were determined as follows:
Where DCt values of the sample and calibrator are determined by subtracting the average Ct value of the target gene from the average Ct value of the RPLP0 gene (Collins et al., 1998) .
Primers and PCR consumables Primers for the RPLP0 and target genes were chosen with the assistance of the computer programs Oligo 4.0 (National Biosciences, Plymouth, MN, USA) and Primer Express (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). We conducted BLASTN searches against dbEST, htgs and nr (the non redundant set of the GenBank, EMBL and DDBJ database sequences) to con®rm the total gene speci®city of the nucleotide sequences chosen for the primers, and the absence of DNA polymorphisms. The nucleotide sequences of the primers are shown in Table   Table 4 Characteristics of the 131 patients, and relation to relapsefree survival Determined at the protein level.
5
Information available for 124 patients 5. To avoid amplifying contaminating genomic DNA, one of the two primers was placed in a dierent exon.
RNA extraction Total RNA was extracted from breast specimens by using the acid-phenol guanidium method. The quality of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under ultraviolet light.
cDNA synthesis RNA was reverse transcribed in a ®nal volume of 20 ml containing 16 RT buer (500 mM each dNTP, 3 mM MgCl 2 , 75 mM KCl, 50 mM Tris-HCl pH 8.3), 10 units of RNasin TM ribonuclease inhibitor (Promega, Madison, WI, USA), 10 mM dithiothreitol, 50 units of Superscript II RNase H-reverse transcriptase (Gibco-BRL, Gaithersburg, MD, USA), 1.5 mM random hexamers (Pharmacia, Uppsala, Sweden) and 1 mg of total RNA. The samples were incubated at 208C for 10 min and 428C for 30 min, and reverse transcriptase was inactivated by heating at 998C for 5 min and cooling at 58C for 5 min.
PCR ampli®cation All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). PCR was performed using the SYBR 1 Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems). The thermal cycling conditions comprised an initial denaturation step at 958C for 10 min and 50 cycles at 958C for 15 s and 658C for 1 min. Experiments were performed with duplicates for each data point.
Statistical analysis
Relapse-free survival was determined as the interval between diagnosis and detection of the ®rst relapses (local and/or regional recurrences, and/or metastases).
Clinical, histological and molecular parameters were compared using the Chi-square test. Spearman rank correlation coecients were used to study the association between continuous variables. Dierences between the two populations were considered signi®cant at con®dence levels greater than 95% (P50.05). Survival distributions were estimated by the Kaplan-Meier method (Kaplan and Meier, 1958) , and the signi®cance of dierences between survival rates was ascertained using the log-rank test (Peto et al., 1977) .
Abbreviations
ERa, estrogen receptor alpha; ERb, estrogen receptor beta; PR, progesterone receptor; RT ± PCR, reverse transcriptase ± polymerase chain reaction; ERE, estrogen response element; RB1, retinoblastoma gene; E1A, enzyme immunoassay 
